Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „mmol“
Suchtreffer
Begriffe & Kennungen
Olanzapine Glenmark · 4.8 · Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (≥ 1.467 14
Eintrag öffnenOlanzapine Glenmark · 4.8 · Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (≥ 1.467 14
Eintrag öffnenOlanzapine Glenmark · 4.8 · Observed for fasting normal levels at baseline (< 1.016 mmol/l) which increased to high (≥ 1.467 14
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Glenmark · 4.8 · mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l - < 1.467 mmol/l) to
Eintrag öffnenOlanzapine Teva · 4.8 · 10 4 Observed for fasting normal levels at baseline (<5.56 mmol/l) which increased to high (≥7 mmol/l). Change
Eintrag öffnenOlanzapine Teva · 4.8 · 28 3 Observed for fasting normal levels at baseline (<5.17 mmol/l) which increased to high (≥6.2 mmol/l). Chan
Eintrag öffnenOlanzapine Viatris (previously Olanzapine Mylan) · 4.8 · 10 3 Observed for fasting normal levels at baseline (< 5.17 mmol/l) which increased to high (≥ 6.2 mmol/l). Ch
Eintrag öffnenPadcev · 4.8 · In clinical studies of enfortumab vedotin as monotherapy, hyperglycaemia (blood glucose >13.9 mmol/L) occurred
Eintrag öffnenPraluent · 4.8 · LDL-C values <0.65 mmol/L (<25 mg/dL)
Eintrag öffnenRepatha · 4.8 · The safety profile was consistent between subjects with post-baseline LDL-C < 25 mg/dL (0.65 mmol/L) or < 40 m
Eintrag öffnenRinvoq · 4.8 · 21 • Total cholesterol ≥ 5.17 mmol/L (200 mg/dL): 49% vs. 11%, in the upadacitinib 45 mg and placebo groups, r
Eintrag öffnenRinvoq · 4.8 · 79 • Total cholesterol ≥ 5.17 mmol/L (200 mg/dL): 49% vs. 11%, in the upadacitinib 45 mg and placebo groups, r
Eintrag öffnenRinvoq · 4.8 · • Total cholesterol ≥ 5.17 mmol/L (200 mg/dL): 62% vs. 31%, in the upadacitinib 15 mg and placebo groups, resp
Eintrag öffnenRinvoq · 4.8 · • Total cholesterol ≥ 5.17 mmol/L (200 mg/dL): 62% vs. 31%, in the upadacitinib 15 mg and placebo groups, resp
Eintrag öffnenSuliqua · 4.8 · The following table describes the rate of documented symptomatic hypoglycaemia (≤ 3.9 mmol/L) and severe hypog
Eintrag öffnenYuvanci · 4.8 · In SERAPHIN, macitentan 10 mg monotherapy was associated with a mean decrease in haemoglobin of 0.69 mmol/L (1
Eintrag öffnen